Hematology News and Research RSS Feed - Hematology News and Research

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.
NCCN Policy Summit to address impact of health care reform on academic oncology practice

NCCN Policy Summit to address impact of health care reform on academic oncology practice

On July 10, 2014, the National Comprehensive Cancer Network® (NCCN®) will host the NCCN Policy Summit: The Impact of Health Care Reform on Academic Oncology Practice, at The Westin Arlington Gateway in Arlington, Virginia, as part of the NCCN Oncology Policy Program. [More]
Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç. [More]
patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL). [More]
HOC pleads guilty for selling misbranded, unapproved chemotherapy drugs

HOC pleads guilty for selling misbranded, unapproved chemotherapy drugs

Hematology and Oncology Center (HOC) PLLC of Somerset, Kentucky has pleaded guilty to federal charges that the firm purchased and sold unapproved and improperly labeled chemotherapy drugs. [More]
Mode of cancer cell recognition opens up new possibilities for leukaemia immunotherapy

Mode of cancer cell recognition opens up new possibilities for leukaemia immunotherapy

Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered a new class of lipids in the leukaemia cells that are detected by a unique group of immune cells. By recognising the lipids, the immune cells stimulate an immune response to destroy the leukaemia cells and suppress their growth. [More]
Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals Incorporated announced the signing of an exclusive global license agreement with TG Therapeutics, Inc. for the development and commercialization of Ligand's Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors. [More]
Physician describes ways to combat post-cancer pain

Physician describes ways to combat post-cancer pain

More and more people are surviving their cancer. Unfortunately, sometimes survival can come with pain. Although many people won't feel any pain after their cancer treatment, some may have chronic, bothersome pain. [More]
Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye. [More]
Research demonstrates association between diversity of gut bacteria and survival

Research demonstrates association between diversity of gut bacteria and survival

New research, published online today in Blood, the Journal of the American Society of Hematology, suggests that the diversity of bacteria in the gastrointestinal tract of patients receiving stem cell transplants may be an important predictor of their post-transplant survival. [More]
Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer. [More]
Findings add surprising new dimension to understanding of antibody repertoires

Findings add surprising new dimension to understanding of antibody repertoires

As elite soldiers of the body's immune response, B cells serve as a vast standing army ready to recognize and destroy invading antigens, including infections and cancer cells. To do so, each new B cell comes equipped with its own highly specialized weapon, a unique antibody protein that selectively binds to specific parts of the antigen. [More]
Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium's Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming panel discussion highlighting the role of Actinium's alpha-particle radiopharmaceuticals in the treatment of leukemia patients. [More]
Survival rates for African-Americans with head and neck cancer not improved in the last 40 years

Survival rates for African-Americans with head and neck cancer not improved in the last 40 years

The national survival rates for African-Americans diagnosed with head and neck cancer have not improved in the last 40 years despite advances in the treatment and management of the disease, University of Missouri School of Medicine researchers have found in a new study. [More]
Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014. [More]
Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

A physician-scientist who developed a personalized immunotherapy for leukemia using patients' own T cells is the recipient of the 2014 Taubman Prize for Excellence in Translational Medical Science, awarded by the A. Alfred Taubman Medical Research Institute at the University of Michigan Medical School. [More]
UIC conducts clinical trial to evaluate three-drug combination therapy for advanced pancreatic cancer

UIC conducts clinical trial to evaluate three-drug combination therapy for advanced pancreatic cancer

Researchers at the University of Illinois at Chicago are conducting a clinical trial to evaluate a new, three-drug combination therapy for advanced pancreatic cancer. [More]
Scientist discovers new path to stop breast cancer cells from invading organs

Scientist discovers new path to stop breast cancer cells from invading organs

The primary cause of death from breast cancer is the spread of tumor cells from the breast to other organs in the body. Northwestern Medicine- scientists have discovered a new pathway that can stop breast cancer cells from spreading. [More]
Breast cancer worry, risk behavior higher among teenage girls

Breast cancer worry, risk behavior higher among teenage girls

Teenage girls with a familial or genetic risk for breast cancer worry more about getting the disease, even when their mother has no history, compared to girls their age with no known high risks, according to new data presented today by researchers from Penn Medicine's Abramson Cancer Center at the annual meeting of the American Society of Clinical Oncology in Chicago (Abstract #9527). [More]

Nonadherence triples relapse risk in African American and Asian children in remission from ALL

An estimated 25 percent of children in remission from acute lymphocytic leukemia (ALL) are missing too many doses of an essential maintenance medication that minimizes their risk of relapse, according to a study published online today in Blood, the Journal of the American Society of Hematology. [More]